Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men

Table 2

Comparison of diagnostic parameters among the study participants.

Variables	PCa ()	Without PCa ()	value
PSA (ng/ml) (median, IQR)	12.1 (6.7–24.2)	8.7 (6.2–14.5)	0.025
PSA category (ng/ml)
4-10	27 (42.9%)	96 (55.2%)	0.0001
10.1-20	16 (25.4%)	60 (34.5%)
>20	20 (31.7%)	18 (10.3%)
PCA3 score (median, IQR)	42.8 (19.9–64.8)	10.1 (6.3–16.7)	0.0001
<15	7 (11.1%)	125 (71.8%)	0.0001
15.1-30.0	14 (22.2%)	37 (21.3%)
30.1-45.0	11 (17.5%)	12 (6.9%)
45.1-60.0	13 (20.6%)	0
>60.0	18 (28.6%)	0
DRE findings
Positive	27 (42.9%)	23 (13.2%)	0.0001
Negative	36 (57.1%)	151 (86.8%)
Prostate volume (ml) (median, IQR)	35.1 (29.8–45.9)	33.9 (28.8–40.1)	0.210
Prostate volume category (ml)
≤40	39 (61.90%)	128 (73.60%)	0.230
40-80	20 (31.70%)	38 (21.80%)
>80	4 (6.30%)	8 (4.60%)

PSA: prostate-specific antigen; PCA3: prostate cancer antigen 3; DRE: digital rectal examination; IQR: interquartile range.